Literature DB >> 26388131

Mortality and morbidity in primarily resected hepatoblastomas in Japan: Experience of the JPLT (Japanese Study Group for Pediatric Liver Tumor) trials.

Eiso Hiyama1, Tomoro Hishiki2, Kenichiro Watanabe2, Kohmei Ida2, Michihiro Yano2, Takaharu Oue2, Tomoko Iehara2, Ken Hoshino2, Katsuyoshi Koh2, Yukichi Tanaka2, Sho Kurihara3, Yuka Ueda3, Yoshiyuki Onitake3.   

Abstract

BACKGROUND: In the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocols (JPLT-1 and 2) for evaluating the cure rate of risk-stratified hepatoblastoma, primary resection was permitted in PRETEXT I and II cases, followed by postoperative chemotherapy.
METHODS: In approximately 500 enrolled cases, resection was performed as the initial treatment in 60 cases, including all 18 PRETEXT I, 30 PRETEXT II, and 12 ruptured cases. The clinical features, surgical procedures, complications, and survival rates were compared in these three groups.
RESULTS: All 18 PRETEXT I cases underwent complete resection by lobectomy or segmentectomy (n=14) or nonanatomical partial hepatectomy (NPH) (n=4). The 30 PRETEXT II cases underwent primary resection by right or left lobectomy (n=16), NPH (n=10), or other procedures (n=4). Of these 30 cases, operational death occurred in 1 newborn, and recurrence occurred in 7 cases (14.6%), including 6 NPH cases and 4 older cases (aged >3years). Of the 12 ruptured cases, 7 (58.3%) showed recurrence. Event-free survival rates at 5years in the 3 groups were 88%, 70%, and 32%, respectively.
CONCLUSIONS: Primary resection for PRETEXT I or II HB cases should be performed by anatomical resection according to strict surgical guidelines. More intensified chemotherapy is required for primary resected cases whose tumors have ruptured.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complication; Hepatoblastoma; Primary resection, survival; Prognosis

Mesh:

Year:  2015        PMID: 26388131     DOI: 10.1016/j.jpedsurg.2015.08.035

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  1 in total

1.  Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib.

Authors:  Dou Yang; Feng Chen; Dan Gong; Lei Zeng; Deng Xiang; Yuanqiao He; Leifeng Chen; Jinlong Yan; Shouhua Zhang
Journal:  Pediatr Surg Int       Date:  2022-01-15       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.